Background: Follicular thyroid tumors harbor several genetic alterations such as RAS mutations and PAX8/PPAR γ rearrangement. The aims of our study were to investigate the prevalence of RAS mutations and PAX8/PPAR γ rearrangement in follicular thyroid tumors and to correlate RAS mutations and/or PAX8/PPAR γ rearrangement with clinicopathologic features in Korean patients with follicular thyroid carcinomas. Methods: RAS mutations were investigated by polymerase chain reaction and DNA sequencing in surgical specimens of 37 follicular thyroid carcinomas (FTCs) and 16 follicular thyroid adenomas (FTAs). PAX8/PPAR γ rearrangement was analyzed by fluorescent in situ hybridization in surgical specimens of 31 FTCs and 13 FTAs. Results: RAS mutations were detected in 30% (11 of 37) of FTCs and 19% (three of 16) of FTAs. Three of 11 FTC patients with RAS mutations died of thyroid cancer, but none of the 26 FTC patients without RAS mutations. PAX8/PPAR γ rearrangement was found in 10% (three of 31) of FTCs, but in none of the 13 FTAs. All three FTC patients with PAX8/PPAR γ rearrangement remained in complete remission during follow-up. There were no FTC patients with both RAS mutations and PAX8/PPAR γ rearrangement.
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PAX8/PPAR γ 재배열 검색

1) Fluorescence in situ hybridization (FISH) probes
FISH 분석을 위한 게놈 클론은 human male bacterial artificial Table 4) . Table 2 . Spectrum of RAS point mutations identified in follicular cell tumors
FTA, follicular thyroid adenoma; FTC, follicular thyroid carcinoma. Table 7) . http://www.enm-kes.org 다( Table 8) 
RAS 변이만 발생된 환자는 여포암
FTA, follicular thyroid adenoma; FTC, follicular thyroid carcinoma; PAX8/PPAR γ (+), positive for PAX8/PPAR γ rearrangement; RAS (+), positive for RAS mutations; RAS (+)/PAX8/PPAR γ (+), positive for both RAS mutations and PAX8/PPAR γ rearrangement; RAS (−)/PAX8/PPAR γ (−), negative for both RAS mutations and PAX8/PPAR γ rearrangement. 
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